NewGenIvf
NIVF
3 hedge funds and large institutions have $3.85K invested in NewGenIvf in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8,865% more capital invested
Capital invested by funds: $43 → $3.85K (+$3.81K)
200% more funds holding
Funds holding: 1 → 3 (+2)
0.02% more ownership
Funds ownership: 0% → 0.03% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.06K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$812 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $3.39K | +$6.06K | +500 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $452 | +$812 | +67 | New |
|
|
SS
3
SBI Securities
Tokyo,
Japan
| $11 | – | – | – |
|
4
Morgan Stanley
New York
| $2 | – | – | – |
|
NIVF Hedge Fund Activity: Q1 2026 in Review
3 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in NewGenIvf (NIVF) for Q1 2026, worth a combined $3.85K — up 8,865% from $43 a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NIVF positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $6.06K.
- 3 institutional investors held NewGenIvf (NIVF) as of Q1 2026, up from 1 in Q4 2025.
- Funds reported $3.85K of NewGenIvf stock for Q1 2026, up 8,865% quarter-over-quarter.
- 2 funds opened new NewGenIvf positions in Q1 2026 and 0 closed out, a net change of +2 holders.
- The largest NewGenIvf buyer in Q1 2026 was Tower Research Capital (TRC), an estimated $6.06K added.
Based on aggregated 13F filings for Q1 2026.